VICL - Vical Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7701
-0.0029 (-0.38%)
As of 1:18PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7730
Open0.7989
Bid0.7720 x 1100
Ask0.7744 x 2200
Day's Range0.7674 - 0.7989
52 Week Range0.7500 - 1.4700
Volume125,036
Avg. Volume210,091
Market Cap17.576M
Beta (3Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.6650
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.80
Trade prices are not sourced from all markets
  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition
    PR Newswirelast month

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

    WeissLaw is investigating whether VICL's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at close of the transaction, VICL shareholders will own only 40% of the combined company.

  • Boulder biotech firm enters reverse merger valued at up to $60 million
    American City Business Journalslast month

    Boulder biotech firm enters reverse merger valued at up to $60 million

    Brickell Biotech Inc., a Boulder-based medical dermatology company, is merging with Vical Inc. (Nasdaq: VICL). Under the terms of the agreement, the combined company will be named Brickell Biotech, keep the management team of Brickell and be headquartered in Boulder. The deal, a reverse merger, will mean Brickell acquires the $35 million that San Diego-based Vical has available as well as its listing on the Nasdaq.

  • GlobeNewswirelast month

    Vical and Brickell Announce Merger Agreement

    Vical Incorporated (“Vical”) (VICL) and Brickell Biotech, Inc. (“Brickell”), a privately-held clinical-stage medical dermatology company, today announced they entered into a definitive merger agreement (the “Merger”) under which Brickell would merge with a wholly-owned subsidiary of Vical in an all-stock transaction. The Merger would create a pharmaceutical company focused on developing novel and differentiated prescription therapies addressing unmet patient needs in hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other debilitating dermatologic disorders. Brickell’s lead pipeline asset, sofpironium bromide, is a pivotal Phase 3-ready topical soft anticholinergic intended for axillary hyperhidrosis.

  • Will Vical (VICL) Report Negative Q1 Earnings? What You Should Know
    Zacks3 months ago

    Will Vical (VICL) Report Negative Q1 Earnings? What You Should Know

    Vical (VICL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GuruFocus.com5 months ago

    Vical Inc (VICL) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Vical Inc had annual average EBITDA growth of 21.60% over the past ten years. Warning! GuruFocus has detected 3 Warning Signs with VICL.

  • Associated Press5 months ago

    Vical: 4Q Earnings Snapshot

    The San Diego-based company said it had a loss of 17 cents per share. The drug developer posted revenue of $124,000 in the period. For the year, the company reported that its loss widened to $16.3 million, ...

  • GlobeNewswire5 months ago

    Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives

    SAN DIEGO, Feb. 19, 2019 -- Vical Incorporated (Nasdaq:VICL) today announced that it has decided to discontinue the Phase 2 clinical trial of VL‑2397 that was initiated in the.

  • Simply Wall St.7 months ago

    What Investors Should Know About Vical Incorporated’s (NASDAQ:VICL) Financial Strength

    The direct benefit for Vical Incorporated (NASDAQ:VICL), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...

  • GlobeNewswire8 months ago

    New Research: Key Drivers of Growth for Interface, USA Truck, Weingarten Realty Investors, Unum Group, Trivago N.V. ADS, and Vical — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 01, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Vical (VICL) Reports Q3 Loss, Misses Revenue Estimates
    Zacks9 months ago

    Vical (VICL) Reports Q3 Loss, Misses Revenue Estimates

    Vical (VICL) delivered earnings and revenue surprises of 36.36% and -73.14%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 months ago

    Vical: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 7 cents. Losses, adjusted for non-recurring gains, were 14 cents per share. The drug developer posted revenue of $47,000 in the period. ...

  • Vical (VICL) Q3 Earnings Preview: What to Know Ahead of the Release
    Zacks9 months ago

    Vical (VICL) Q3 Earnings Preview: What to Know Ahead of the Release

    Vical (VICL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Simply Wall St.9 months ago

    Who Are The Major Shareholders In Vical Incorporated (NASDAQ:VICL)?

    The big shareholder groups in Vical Incorporated (NASDAQ:VICL) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership Read More...

  • Vical (VICL) Reports Q2 Loss, Tops Revenue Estimates
    Zacks11 months ago

    Vical (VICL) Reports Q2 Loss, Tops Revenue Estimates

    Vical (VICL) delivered earnings and revenue surprises of 18.52% and 44.12%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press11 months ago

    Vical: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 22 cents. The drug developer posted revenue of $735,000 in the period. The company's shares closed at $1.35. A year ago, they were ...